MANNKIND CORP Restructuring Reserve, Settled without Cash
MANNKIND CORP (MNKD) reported Restructuring Reserve, Settled without Cash of $1.01 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-02-27.
Discontinued › Notes › Restructuring and Related Activities
us-gaap:RestructuringReserveSettledWithoutCash2 · last filed 2018-02-27
- MANNKIND CORP restructuring reserve, settled without cash for the quarter ending 2017-12-31 was $0.00, a 100.00% decline year-over-year.
- MANNKIND CORP restructuring reserve, settled without cash for the quarter ending 2017-09-30 was $0.00.
- MANNKIND CORP restructuring reserve, settled without cash for the quarter ending 2017-06-30 was $410.00K.
- MANNKIND CORP restructuring reserve, settled without cash for the quarter ending 2017-03-31 was $604.00K.
- MANNKIND CORP restructuring reserve, settled without cash for fiscal 2017 was $1.01M, a 72.50% decline from fiscal 2016.
- MANNKIND CORP restructuring reserve, settled without cash for fiscal 2016 was $3.69M, a 22.41% increase from fiscal 2015.
- MANNKIND CORP restructuring reserve, settled without cash for fiscal 2015 was $3.01M.
| Period end | Restructuring Reserve, Settled without Cash 3 month | Restructuring Reserve, Settled without Cash 6 month | Restructuring Reserve, Settled without Cash 9 month | Restructuring Reserve, Settled without Cash 12 month |
|---|---|---|---|---|
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | $0.00 derived: sum of 2 quarters · filed 2018-02-27 | $410.00K derived: sum of 3 quarters · filed 2018-02-27 | $1.01M 10-K · filed 2018-02-27 |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $410.00K derived: sum of 2 quarters · filed 2017-11-07 | $1.01M 10-Q · filed 2017-11-07 | $2.84M derived: sum of 4 quarters · filed 2018-02-27 |
| 2017-06-30 | $410.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-07 | $1.01M 10-Q · filed 2017-08-07 | $2.84M derived: sum of 3 quarters · filed 2018-02-27 | |
| 2017-03-31 | $604.00K 10-Q · filed 2017-05-10 | $2.43M derived: sum of 2 quarters · filed 2018-02-27 | ||
| 2016-12-31 | $1.82M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | $3.69M 10-K · filed 2018-02-27 | ||
| 2016-09-30 | $1.86M 10-Q · filed 2016-11-09 | |||
| 2015-12-31 | $3.01M 10-Q · filed 2016-11-09 | $3.01M 10-K · filed 2017-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |